FindTrial
Sign In

To evaluate the safety and efficacy of Cynatine HNS (hydrolyzed keratine peptide capsule 250 mg)

A Randomized, Double-blind, Placebo-controlled, Parallel group, Observational Clinical Trial to evaluate the safety and efficacy of Cynatine HNS (hydrolyzed keratine peptide capsule 250 mg) Versus Maltodextrin Oral Capsule on hair and nail parameters.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/01/023074
Enrollment
48
Registered
2020-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 3- Administration

Interventions

Intervention1: Cynatine HNS (hydrolyzed keratine peptide capsule 250 mg): 250 mg Orally twice daily Duration 14 days Control Intervention1: Maltodextrin Oral Capsule: One capsule twice daily Duration

Sponsors

Maxcure Nutravedics Ltd
Lead Sponsor
Mudra Clincare
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. All subjects willing to fill and sign ICFs [Informed Consent Forms] 2. Only females having age >= 25 to 3. Females having clinical signs of stressed or damaged hairs. 4. Females with an agreement, not to use other possible cosmetic treatments which could interfere with the study. 5. Subject able to follow study procedures. 6. In generally good health. 7. Female, using birth control 8. Subjects who are able and are willing to comply with the protocol 9. Subjects ready to follow-up for entire duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects unwilling to sign on ICF 2. Any dermatological condition of the scalp other than hair loss and /or dandruff. 3. Any prior hair growth procedures (e.g., hair transplant or laser) 4. History of alcohol or drug addiction 5. History of skin allergy 6. Any active skin infection in the scalp area or scarring in the target area. 7. Subject had ever received radiation therapy to the scalp, or had chemotherapy within the past year. 8. Subject had participated in any investigational study within the 30 days prior to trial. 9. A history or the presence of any serious and/or chronic medical condition(s) including psychiatric illnesses] which, in the opinion of the investigator, may cause harm to the individual and/or compromise/confound the study results. 10. Subjects unwilling or unable to comply with the study procedures

Design outcomes

Primary

MeasureTime frame
1. Change in hair and nail parameters 2. Physicianâ??s and subjectsâ?? Global AssessmentTimepoint: 1. Visit 3,4 and 5 2. Visit 5—

Secondary

MeasureTime frame
1. Number of participants reporting adverse events 2. Mean change in the vital parameters from baseline to each post randomization visitTimepoint: 1. by Visit 2,3,4 and 5 2. Visit 1 to 5—

Countries

India

Contacts

Public ContactDr Harshad Dabhade

Rajpal Hospital, Navi Mumbai

mudraclincare@gmail.com8291745386

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026